Suggested remit: To appraise the clinical and cost effectiveness of sparsentan within its marketing authorisation for treating primary IgA nephropathy.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6308

Provisional Schedule

Committee meeting 11 February 2025
Expected publication 30 April 2025

Project Team

Project lead Celia Mayers

Email enquiries

Stakeholders

Companies sponsors Vifor Pharma (sparsentan)
Others Department of Health and Social Care
  NHS England
Patient carer groups Kidney Research UK
Professional groups Royal College of Physicians
  UK Kidney Association
Associated public health groups None
Comparator companies Advanz pharma (acetazolamide, amiloride hydrochloride) – confidentiality agreement not signed, not participating
  AstraZeneca (dapagliflozin) – confidentiality agreement not signed, not participating
  Atnahs pharma (chlortalidone, lisinopril) – confidentiality agreement not signed, not participating
  Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan) – confidentiality agreement not signed, not participating
  Boehringer Ingelheim (empagliflozin, telmisartan) – confidentiality agreement not signed, not participating
  Bristol laboratories (lisinopril) – confidentiality agreement not signed, not participating
  Brown & Burk (irbesartan, lisinopril, ramipril, telmisartan, losartan) – confidentiality agreement not signed, not participating
  Chemidex pharma (bumetanide) – confidentiality agreement not signed, not participating
  Daiichi Sankyo (olmesartan) – confidentiality agreement not signed, not participating
  Dexcel pharma (enalapril, losartan) – confidentiality agreement not signed, not participating
  Essential pharma (amiloride hydrochloride) – confidentiality agreement not signed, not participating
  Genus Pharmaceuticals Holdings Ltd [STADA] (targeted-release budesonide) – confidentiality agreement not signed, not participating
  Glenmark pharma (olmesartan, perindopril, telmisartan) – confidentiality agreement not signed, not participating
  Ipca laboratories (furosemide) – confidentiality agreement not signed, not participating
  Martindale pharma (captopril) – confidentiality agreement not signed, not participating
  Menarini Farmaceutica Internazionale SRL (canagliflozin) – confidentiality agreement not signed, not participating
  Merck Sharp & Dohme (ertugliflozin) – confidentiality agreement not signed, not participating
  Morningside healthcare (chlortalidone) – confidentiality agreement not signed, not participating
  Mylan (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide) – confidentiality agreement not signed, not participating
  Neon healthcare (candesartan) – confidentiality agreement not signed, not participating
  Novartis (valsartan)
  Organon Pharma (enalapril, losartan) – confidentiality agreement not signed, not participating
  Pfizer (quinapril) – confidentiality agreement not signed, not participating
  Pinewood healthcare (furosemide) – confidentiality agreement not signed, not participating
  Rosemont pharmaceuticals (furosemide, bumetanide, lisinopril, ramipril) – confidentiality agreement not signed, not participating
  Sandoz (candesartan, cyclophosphamide, losartan, perindopril, ramipril, telmisartan) – confidentiality agreement not signed, not participating
  Sanofi (furosemide, irbesartan, ramipril) – confidentiality agreement not signed, not participating
  Servier laboratories (indapamide, perindopril) – confidentiality agreement not signed, not participating
  Sigma pharmaceuticals (indapamide) – confidentiality agreement not signed, not participating
  Strides pharma (indapamide) – confidentiality agreement not signed, not participating
  Takeda (azilsartan) – confidentiality agreement not signed, not participating
  Ten pharma (captopril) – confidentiality agreement not signed, not participating
  Thame laboratories (captopril, furosemide) – confidentiality agreement not signed, not participating
  Thornton & Ross (olmesartan) – confidentiality agreement not signed, not participating
  Tillomed laboratories (perindopril, amiloride hydrochloride) – confidentiality agreement not signed, not participating
  Zentiva (indapamide, irbesartan, ramipril, valsartan) – confidentiality agreement not signed, not participating
Evidence review group School of Health and Related Research (ScHARR)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health – Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
23 May 2024 Following a request from the company, Vifor Pharma, the timelines for this appraisal have been revised. The deadline for submissions is now 11 September 2024. The appraisal committee meeting will now be held on 11 February 2025.
05 March 2024 Invitation to participate
15 September 2023 - 13 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6308
03 August 2023 In progress. DHSC referral received
07 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual